Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508551 | 0.80 | ATM (0.45) | KDM4EALDH1A1P2RX4SSTR4SIGMAR1 | |
| SCHEMBL2016562 | 0.80 | KDM4E (0.49) | KDM4EALDH1A1P2RX4SSTR4SIGMAR1 | |
| SCHEMBL26369198 | 0.79 | KDM4E (0.41) | KDM4EALDH1A1P2RX4SSTR4SIGMAR1 | |
| SCHEMBL1490713 | 0.78 | KDM4E (0.43) | KDM4EALDH1A1P2RX4SSTR4SIGMAR1 | |
| SCHEMBL19457387 | 0.78 | KDM4E (0.43) | KDM4EALDH1A1P2RX4SSTR4SIGMAR1 | |
| SCHEMBL15796814 | 0.78 | KDM4E (0.43) | KDM4EALDH1A1P2RX4SSTR4SIGMAR1 | |
| SCHEMBL8647513 | 0.78 | — | — | |
| SCHEMBL12789742 | 0.78 | ALDH1A1 (0.50) | KDM4EALDH1A1P2RX4SSTR4SIGMAR1 | |
| SCHEMBL10271099 | 0.77 | EPHX2 (0.46) | KDM4EALDH1A1P2RX4 | |
| SCHEMBL22906115 | 0.77 | KDM4E (0.45) | KDM4EALDH1A1P2RX4SSTR4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3801553-B1 | PRODRUGS OF FULVESTRANT | KASHIV BIOSCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20210253626-A1 | PRODRUGS OF FULVESTRANT | KI PHARMACEUTICALS, LLC | 2021-08-19 | — | — | US | disclosed |
| EP-3801553-A2 | PRODRUGS OF FULVESTRANT | Kashiv Biosciences, LLC (US) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253626-A1 | PRODRUGS OF FULVESTRANT | CYP19A1, PGR, CYP21A2 | KDM4E 775/4885ALDH1A1 746/4885P2RX4 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.